Treatment using neublastin polypeptides
AssigneeBiogen Idec MA Inc.
InventorDinah W. Y. Sah
Life of this patent
Estimating the term…
Abstract
The invention relates to treatments of neuropathic pain, including tactile allodynia, and to treatments for reducing loss of pain sensitivity associated with neuropathy. The present treatments involve the use of neublastin (NBN) polypeptides.
Claims27
A method for treating neuropathic pain in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide, wherein the pharmaceutical composition is administered to the subject via systemic delivery.
(canceled)
6-9. (canceled)
11-12. (canceled)
A method for treating neuropathic pain in a subject comprising:
- a) administering to the subject an effective amount of a neublastin polypeptide;
- and
- b) administering to the subject an effective amount of an analgesia-inducing compound selected from the group consisting of opioids, anti-arrhythmics, topical analgesics, local anaesthetics, anticonvulsants, antidepressants, corticosteroids and NSAIDS.
14-26. (canceled)
(canceled)
(canceled)
A method for reducing the loss of pain sensitivity in a subject afflicted with a neuropathy, the method comprising administering a formulation comprising a neublastin polypeptide at a dosage of between 1 ug/kg to 30,000 ug/kg body weight of the subject, per dose.
41-56. (canceled)
A method for treating allodynia in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide.
A method for treating hyperalgesic pain in a subject, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a neublastin polypeptide.
Dependencies are inferred from the claim text.